Welcome to the e-CCO Library!

OP40: Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn’s Disease patients in the STARDUST trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Danese, S.(1);Vermeire, S.(2);Dignass, A.(3);Panés, J.(4);D'Haens, G.(5);Magro, F.(6,7);Le Bars, M.(8);Nazar, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14)
Created: Wednesday, 2 June 2021, 4:12 PM
OP40: Efficacy of risankizumab induction and maintenance therapy by baseline Crohn’s Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies
Year: 2022
Source: ECCO'22
Authors: Bossuyt, P.(1);Bresso, F.(2);Dubinsky, M.(3);Ha, C.(4);Siegel, C.(5);Zambrano, J.(6);Kligys, K.(6);Kalabic, J.(6);Zhang, Y.(6);Panaccione, R.(7);
Created: Friday, 11 February 2022, 3:52 PM
OP40: PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study Results
Year: 2023
Source: ECCO’23 Copenhagen
Authors: B. Sands*(1), L. Peyrin-Biroulet(2), S. Danese(3), D.T. Rubin(4), S. Vermeire(5), O. Laurent(6), A. Luo(6), D. Nguyen(6), JD. Lu(6),A. Wiechowska-Kozlowska(7), J. Leszczyszyn(8), R. Kempinski(9), J. Kierkus(10), C. Ma(11), T. Ritter*(12), B.G. Feagan(13), S. Targan*(14)
Created: Friday, 14 July 2023, 10:43 AM
P001 The novel DYRK1a inhibitor VRN024219 alleviates disease severity on the IBD mouse models by modulating T-cell differentiation
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.H. Seo1, H.W. Ma2,3, S. Kim1, D.H. Kim2, H.K. Kim4, S.H. Lee1, S. Kim1, J.Y. Ahn5, S.H. Yoon5, D.K. Kim1, J.H. Cheon2,3,6

Created: Thursday, 30 January 2020, 10:12 AM
P001: Comparison of in vivo T cell homing to the inflamed gut with the etrolizumab surrogate antibody FIB504 and vedolizumab in a humanised mouse model
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Zundler*, A. Fischer, R. Atreya, C. Neufert, I. Atreya, M. F. Neurath

Created: Friday, 22 February 2019, 9:49 AM
P001: Establishment of in vitro human model for ulcerative colitis by using human colon organoid culture
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Hibiya1*, K. Tsuchiya1, S. Watanabe1, R. Nishimura1, T. Shirasaki1, S. Oshima1, R. Okamoto1, T. Nakamura2, M. Watanabe3

Created: Thursday, 21 February 2019, 9:14 AM
P001: Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on the IL23/IFNg axis
Year: 2022
Source: ECCO'22
Authors: Lo, J.(1);Cozzetto, D.(1);Madgwick, M.(2,3);Sieh, J.Y.X.S.(4);Olbei, M.(2,3);Alexander, J.L.(1);Miguens Blanco, J.(1);Kudo, H.(1);Ibraheim, H.(1);Liu, Z.(1);Castro Seoane, R.(1);Goldin, R.(1);Marchesi, J.(1);Korcsmaros, T.(1,2,3);Lord, G.(5);Powell, N.(1);
Created: Friday, 11 February 2022, 3:52 PM
P001: Multi-omic data integration assisted identification of molecular features contributing to disease heterogeneity in Crohn's disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Sudhakar*1,2,3, B. Verstockt1,4, B. Creyns5, J. Cremer5, G. van Assche1,4, T. Korcsmaros2,3, M. Ferrante1,4, S. Vermeire1,4

Created: Friday, 22 February 2019, 9:41 AM
P001: Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Santo, J.(1)*;Gineste, P.(1);Scherrer, D.(2);Nitcheu, J.(1);Ehrlich, H.(3);Sands, B.E.(4);Vermeire, S.(5);
Created: Friday, 14 July 2023, 10:43 AM
P001: Succinate, a gut microbiota-derived metabolite, modulates the inflammatory status of the creeping fat in Crohn’s disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Serena, C.(1);Monfort-Ferre, D.(1);Bautista, M.(2);Menacho, M.(2);Martí, M.(3);Espin, E.(3);Vendrell, J.(1);Fernández-Veledo, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P001: The biomarker profile of PTG-200, an oral peptide antagonist of IL-23 receptor, tracks with efficacy in a preclinical model of IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Cheng X., Taranath R., Mattheakis L., Bhandari A., Liu D.

Created: Wednesday, 20 February 2019, 10:36 AM
P002 Specific genome editing to model hypermethylation of the SP140 gene that associates to Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

I. Hageman1, A. Li Yim2, V. Joustra3, M. Ghiboub1, K. Gecse3, A. Te Velde1, G. D’Haens3, C. Paulusma1, P. Henneman2, W. De Jonge1

Created: Thursday, 30 January 2020, 10:12 AM
P002: Beneficial effects of blocking EphBs-ephrinBs forward signalling in a murine Crohn’s sisease (CD) model
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Grandi, I. Zini, M. Tognolini, V. Ballabeni, E. Barocelli, S. Bertoni*

Created: Friday, 22 February 2019, 9:49 AM
P002: Endoscopic placement of a drug-eluting platform with monoclonal antibodies in an animal model of experimental colitis by TNBS: effect on disease outcome and anti-drug antibodies (ADA’s) formation
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Bon-Romero1,2, R. Bartolí1,2,3, N. De la Ossa4, V. Moreno de Vega2, I. Marín2, E. Domènech1,2,3, V. Lorenzo-Zúñiga1,2,3

Created: Friday, 22 February 2019, 9:41 AM
P002: Epithelial to mesenchymal transition is a hallmark of fibrostenosing Crohn’s disease and is associated with down regulation of the miR-200 family
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.J. Mehta1*, A. Lewis1, A. Nijhuis1, R. Jeffery1, R. Feakins1,2, A. Silver1, J.O. Lindsay1,3

Created: Thursday, 21 February 2019, 9:14 AM
P002: Exclusive Enteral Nutrition, the gut microbiome and corticosteroid response in patients with acute severe colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Bajaj, A.(1)*;Markandey, M.(1);Vuyyuru, S.(1);Mohta, S.(1);Singh, M.(1);Verma, M.(1);Kumar, S.(1);Kante, B.(1);Kumar, P.(1);Makharia, G.(1);Kedia, S.(1);Travis, S.(2);Ahuja, V.(1);
Created: Friday, 14 July 2023, 10:43 AM
P002: Glial cell line-Derived Neurotrophic Factor (GDNF) improves intestinal wound healing – A new target for IBD treatment?
Year: 2022
Source: ECCO'22
Authors: Kelm, M.(1);Burkard, N.(1);Hoerner, M.(1);Germer, C.T.(1);Schlegel, N.(1);Flemming, S.(1);
Created: Friday, 11 February 2022, 3:52 PM
P002: Inhibition of Axl signaling by BGB324 reduces fibrogenesis in human intestinal cells and human intestinal organoids
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Steiner C.1, Rodansky E.2, Johnson L.A.2, Huang S.2, Spence J.1, Higgins P.D.*3

Created: Wednesday, 20 February 2019, 10:36 AM
P002: Methodological development of single-cell phenotyping and spatial analysis of intestinal leukocyte, stromal and epithelial cell populations in inflammatory bowel disease formalin fixed paraffin embedded tissue by Hyperion imaging mass cytometry
Year: 2021
Source: ECCO'21 Virtual
Authors: Lamb, C.A.(1,2);Doyle, J.(1);Hulme, G.(3);Cooke, K.(1);Au-Yeung, A.(4);Ojeda-Garcia, J.(3);Fuller, A.(3);McDonald, D.(3);Mansfield, J.C.(1,2);Kirby, J.A.(1);McBride, J.(4);Speight, R.A.(1,2);O’Gorman, W.(4);Filby, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P003 Metabolomics for improved patient stratification in inflammatory bowel disease: Characterisation of the ulcerative colitis metabolome
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J. Diab1, T. Hansen1, R. Goll2,3, H. Stenlund4, E. Jensen1, T. Moritz4,5, J. Florholmen2,3, G. Forsdahl1

Created: Thursday, 30 January 2020, 10:12 AM